{"id":"NCT03465722","sponsor":"Blueprint Medicines Corporation","briefTitle":"(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST","officialTitle":"An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-26","primaryCompletion":"2020-03-09","completion":"2021-09-15","firstPosted":"2018-03-14","resultsPosted":"2021-05-14","lastUpdate":"2022-10-06"},"enrollment":476,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["GIST"],"interventions":[{"type":"DRUG","name":"avapritinib","otherNames":["BLU-285"]},{"type":"DRUG","name":"regorafenib","otherNames":["Stivarga"]}],"arms":[{"label":"avapritinib","type":"EXPERIMENTAL"},{"label":"regorafenib","type":"ACTIVE_COMPARATOR"}],"summary":"This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.","primaryOutcome":{"measure":"Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST), Version 1.1","timeFrame":"24 Months","effectByArm":[{"arm":"Avapritinib","deltaMin":4.2,"sd":null},{"arm":"Regorafinib","deltaMin":5.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":114,"countries":["United States","Australia","Austria","Belgium","Canada","China","Czechia","France","Germany","Hungary","Italy","Netherlands","Poland","Singapore","South Korea","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["37105265","34343033","30274985"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":106,"n":239},"commonTop":["Palmar-plantar erythrodysaesthesia syndrome","Dysphonia","Weight decreased","Headache","Periorbital oedema"]}}